(Reuters) - GlaxoSmithKline signed a collaboration agreement with the MD Anderson Cancer Center in Houston to develop new drugs that promote a patient's immune system to attack cancer based on discoveries by Anderson researchers. Anderson, one of the world's premier cancer research and treatment centers, announced the agreement on Friday. Under terms of the deal, it will receive an undisclosed upfront payment and research funding from Glaxo and could earn $335 million plus royalties if the collaboration leads to approved medicines. ... Click here to read the rest
No comments:
Post a Comment